Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology

NMR in Biomedicine

Volumn 25, Issue 9, 2012, Pages 1073-1087

  Shungu, Dikoma C ^a   Weiduschat, Nora ^a   Murrough, James W ^b   Mao, Xiangling ^a   Pillemer, Sarah ^b   Dyke, Jonathan P ^a   Medow, Marvin S ^c   Natelson, Benjamin H ^d   Stewart, Julian M ^c   Mathew, Sanjay J ^b,e  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

^d BETH ISRAEL MEDICAL CENTER   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Arterial spin labeling; Cerebral blood flow; Cerebrospinal fluid, glutathione; Chronic fatigue syndrome; Lactate; Major depressive disorder; MRS

Indexed keywords

ARTERIAL SPIN LABELING; CEREBRAL BLOOD FLOW; CHRONIC FATIGUE SYNDROMES; GLUTATHIONES; LACTATE; MAJOR DEPRESSIVE DISORDER; MRS;

CEREBROSPINAL FLUID; NEUROIMAGING; OXIDATIVE STRESS; PEPTIDES;

BRAIN;

GLUTATHIONE; LACTIC ACID;

ADULT; ANTERIOR CINGULATE; ARTICLE; BRAIN BLOOD FLOW; BRAIN CORTEX; CEREBROSPINAL FLUID; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISABILITY; FEMALE; HEALTH; HUMAN; HUMAN TISSUE; LINGUAL GYRUS; MAJOR DEPRESSION; MALE; METABOLITE; MITOCHONDRION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERFUSION; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTON NUCLEAR MAGNETIC RESONANCE; SPIN LABELING;

ADOLESCENT; ADULT; CEREBRAL CORTEX; CEREBRAL VENTRICLES; CEREBROVASCULAR CIRCULATION; DEMOGRAPHY; FATIGUE SYNDROME, CHRONIC; FEMALE; GLUTATHIONE; HUMANS; LACTIC ACID; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OCCIPITAL LOBE; ORGAN SIZE; OXIDATIVE STRESS; PHOSPHATES; REGIONAL BLOOD FLOW; SPIN LABELS; YOUNG ADULT;

EID: 84865296409     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.2772     Document Type: Article

References (50)

1. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International chronic fatigue syndrome study group. Ann. Intern. Med. 1994; 121: 953-959.
2. Afari N, Buchwald D. Chronic fatigue syndrome: a review. Am. J. Psychiatry 2003; 160: 221-236.
3. 1H MRS imaging study. NMR Biomed. 2009; 22: 251-258.
4. 1H MRS imaging at 3T. II: comparison with major depressive disorder. NMR Biomed. 2010; 23: 643-650.
5. Pall ML. Elevated, sustained peroxynitrite levels as the cause of chronic fatigue syndrome. Med. Hypotheses 2000; 54: 115-125.
6. Kennedy G, Spence VA, McLaren M, Hill A, Underwood C, Belch JJ. Oxidative stress levels are raised in chronic fatigue syndrome and are associated with clinical symptoms. Free Radic. Biol. Med. 2005; 39: 584-589.
7. Robinson M, Gray SR, Watson MS, Kennedy G, Hill A, Belch JJ, Nimmo MA. Plasma IL-6, its soluble receptors and F-isoprostanes at rest and during exercise in chronic fatigue syndrome. Scand. J. Med. Sci. Sports 2009; 13: 1-9.
8. Ichise M, Salit IE, Abbey SE, Chung DG, Gray B, Kirsh JC, Freedman M. Assessment of regional cerebral perfusion by 99Tcm-HMPAO SPECT in chronic fatigue syndrome. Nucl. Med. Commun. 1992; 13: 767-772.
9. Schwartz RB, Garada BM, Komaroff AL, Tice HM, Gleit M, Jolesz FA, Holman BL. Detection of intracranial abnormalities in patients with chronic fatigue syndrome: comparison of MR imaging and SPECT. Am. J. Roentgenol. 1994; 162: 935-941.
10. Yoshiuchi K, Farkas J, Natelson BH. Patients with chronic fatigue syndrome have reduced absolute cortical blood flow. Clin. Physiol. Funct. Imaging 2006; 26: 83-86.
11. Biswal B, Kunwar P, Natelson BH. Cerebral blood flow in chronic fatigue syndrome assessed by arterial spin labeling. J. Neurol. Sci. 2010; 301: 9-11.
12. Bains JS, Shaw CA. Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. Brain Res. Brain Res. Rev. 1997; 25: 335-358.
13. Detre JA, Alsop DC. Perfusion magnetic resonance imaging with continuous arterial spin labeling: methods and clinical applications in the central nervous system. Eur. J. Radiol. 1999; 30:115-124.
14. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis Disorders (SCID). New York State Psychiatric Institute, Biometrics Research: New York; 1995.
15. Smets EM, Garssen B, Bonke B, De Haes JC. The multidimensional fatigue inventory (MFI) psychometric qualities of an instrument to assess fatigue. J. Psychosom. Res. 1995; 39: 315-325.
16. Hays RD, Sherbourne CD, Mazel RM. The RAND 36-Item Health Survey 1.0. Health Econ. 1993; 2: 217-227.
17. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int. Clin. Psychopharmacol. 1996; 11(Suppl. 3): 89-95.
18. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann. Acad. Med. Singapore 1994; 23(2): 129-138.
19. Buysse DJ, Reynolds CF, 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989; 28(2): 193-213.
20. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R, Thase ME, Kocsis JH, Keller MB. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol. Psychiatry 2003; 54: 573-583; Erratum in Biol. Psychiatry, 2003; 54: 585.
21. Bernstein DP, Fink L, Handelsman L, Foote J, Lovejoy M, Wenzel K, Sapareto E, Ruggiero J. Initial reliability and validity of a new retrospective measure of child abuse and neglect. Am. J. Psychiatry 1994; 151: 1132-1136.
22. Duyn JH, Gillen J, Sobering G, van Zijl PC, Moonen CT. Multisection proton MR spectroscopic imaging of the brain. Radiology 1993; 188: 277-282.
23. 1H NMR measurements of γ-aminobutyric acid in human brain in vivo. Proc. Natl. Acad. Sci. USA 1993; 90: 5662-5666.
24. Terpstra M, Henry PG, Gruetter R. Measurement of reduced glutathione (GSH) in human brain using LCModel analysis of difference-edited spectra. Magn. Reson. Med. 2003; 50: 19-23.
25. Markwardt CB. Non-linear least squares fitting in IDL with MPFIT. In Proceedings of Astronomical Data Analysis Software and Systems XVIII, Quebec City, QC, Canada, 2008, ASP Conference Series, Vol. 411. Bohlender D, Dowler P, Durand D (eds). Astronomical Society of the Pacific: San Francisco; 2009, pp. 251-254. The IDL fitting routine, 'MPFIT', is available at http://purl.com/net/mpfit, Last Modified on 21 December 2011 by Craig Markwardt.
26. Marshall I, Bruce SD, Higinbotham J, MacLullich A, Wardlaw JM, Ferguson KJ, Seckl J. Choice of spectroscopic lineshape model affects metabolite peak areas and area ratios. Magn. Reson. Med. 2000; 44: 646-649.
27. Doyle TJ, Bedell BJ, Narayana PA. Relative concentrations of proton MR visible neurochemicals in gray and white matter in human brain. Magn. Reson. Med. 1995; 33: 755-759.
28. 1H spectroscopic imaging of human brain at 4.1T using image segmentation. Magn. Reson. Med. 1996; 36: 21-29.
29. Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int. J. Neuropsychopharm. 2008; 11: 851-876.
30. Michel TM, Frangou S, Thiemeyer D, Camara S, Jecel J, Nara K, Brunklaus A, Zoechling R, Riederer P. Evidence for oxidative stress in the frontal cortex in patients with recurrent depressive disorder - a postmortem study. Psychiatry Res. 2007; 151: 145-150.
31. Puri BK, Agour M, Gunatilale KDR, Fernando KAC, Gurusinghe AI, Treasaden IH. An in vivo proton neurospectroscopy study of cerebral oxidative stress in myalgic encephalomyelitis (chronic fatigue syndrome). Prostaglandins Leukot. Essent. Fatty Acids 2009; 81: 303-305.
32. Price RB, Shungu DC, Mao X, Nestadt P, Kelly C, Collins KA, Murrough JW, Charney DS, Mathew SJ. Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder. Biol. Psychiatry 2009; 65: 792-800.
33. Sanacora G, Gueorguieva R, Epperson CN, Wu YT, Appel M, Rothman DL, Krystal JH, Mason GF. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch. Gen. Psychiatry 2004; 61: 705-713.
34. Bhagwagar Z, Wylezinska M, Jezzard P, Evans J, Boorman EM, Matthews PJ, Cowen P. Low GABA concentrations in occipital cortex and anterior cingulate cortex in medication-free, recovered depressed patients. Int. J. Neuropsychopharmacol. 2008; 11: 255-260.
35. Hasler G, van der Veen JW, Tumonis T, Meyers N, Shen J, Drevets WC. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry 2007; 64: 193-200.
36. Richards RS, Roberts TK, McGregor NR, Dunstan RH, Butt HL. Blood parameters indicative of oxidative stress are associated with symptom expression in chronic fatigue syndrome. Redox Rep. 2000; 5: 35-41.
37. Manuel Y, Keenoy B, Moorkens G, Vertommen J, Noe M, Ne've J, De Leeuw I. Magnesium status and parameters of oxidant-antioxidant balance in patients with chronic fatigue syndrome. J. Am. Coll. Nutr. 2000; 19: 374-382.
38. Zeevalk GD, Razmpour R, Bernard LP. Glutathione and Parkinson's disease: is this the elephant in the room? Biomed. Pharmacother. 2008; 62: 236-249.
39. Costa DC, Tannock C, Brostoff J. Brainstem perfusion is impaired in chronic fatigue syndrome. Q. J. Med. 1997; 88: 767-773.
40. Lewis DH, Mayberg HS, Fischer ME, Goldberg J, Ashton S, Graham MM, Buchwald D. Monozygotic twins discordant for chronic fatigue syndrome: regional cerebral blood flow SPECT. Radiology 2001; 219: 766-773.
41. Fischler B, D'Haenen H, Cluydts R, Michiels V, Demets K, Bossuyt A, Kaufman L, De Meirleir K. Comparison of 99m Tc HMPAO SPECT scan between chronic fatigue syndrome, major depression and healthy controls: an exploratory study of clinical correlates of regional cerebral blood flow. Neuropsychobiology 1996; 34: 175-183.
42. 2. J. Appl. Physiol. 1990; 68: 833-842.
43. Kaufmann P, Shungu DC, Sano MC, Jhung S, Engelstad K, Mitsis E, Mao X, Shanske S, Hirano M, DiMauro S, De Vivo DC. Cerebral lactic acidosis correlates with neurological impairment in MELAS. Neurology 2004; 62: 1297-1302.
44. Federico F, Conte C, Simone IL, Giannini P, Liguori M, Picciola E, Tortorella C, Ferrari E. Proton magnetic resonance spectroscopy in patients with ischemic stroke. Ital. J. Neurol. Sci. 1994; 15: 413-420.
45. 2-Isoprostanes in human health and diseases: from molecular mechanisms to clinical implications. Antioxid. Redox Signaling 2008; 10: 1405-1434.
46. Salvemini D, Doyle TM, Cuzzocrea S. Superoxide, peroxynitrite and oxidative/nitrative stress in inflammation. Biochem. Soc. Trans. 2006; 34: 965-970.
47. Hoffman SW, Moore S, Ellis EF. Isoprostanes. Free radical-generated prostaglandins with constrictor effects on cerebral arterioles. Stroke 1997; 28: 844-849.
48. Zeevalk GD, Bernard LP, Song C, Gluck M, Ehrhart J. Mitochondrial inhibition and oxidative stress: reciprocating players in neurodegeneration. Antioxid. Redox Signal. 2005; 7: 1117-1139.
49. Rango M, Bozzali M, Prelle A, Scarlato G, Bresolin N. Brain activation in normal subjects and in patients affected by mitochondrial disease without clinical central nervous system involvement: a phosphorus magnetic resonance spectroscopy study. J. Cerebr. Blood Flow Metab. 2001; 21: 85-91.
50. Rango M, Bonifati C, Bresolin N. Parkinson's disease and brain mitochondrial dysfunction. A functional phosphorus magnetic resonance spectroscopy study. J. Cerebr. Blood Flow Metab. 2006; 26: 283-290.